Atria Investments Inc Makes New Investment in InMode Ltd. (NASDAQ:INMD)

Atria Investments Inc acquired a new position in InMode Ltd. (NASDAQ:INMD) during the third quarter, according to its most recent 13F filing with the SEC. The firm acquired 12,260 shares of the healthcare company’s stock, valued at approximately $208,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Systematic Financial Management LP increased its position in InMode by 34.5% during the 2nd quarter. Systematic Financial Management LP now owns 866,619 shares of the healthcare company’s stock worth $15,807,000 after purchasing an additional 222,532 shares in the last quarter. ARK Investment Management LLC increased its position in shares of InMode by 35.0% in the second quarter. ARK Investment Management LLC now owns 124,905 shares of the healthcare company’s stock worth $2,278,000 after acquiring an additional 32,369 shares in the last quarter. Hsbc Holdings PLC raised its stake in shares of InMode by 129.7% in the 2nd quarter. Hsbc Holdings PLC now owns 90,280 shares of the healthcare company’s stock valued at $1,659,000 after acquiring an additional 50,974 shares during the period. North Growth Management Ltd. lifted its holdings in shares of InMode by 11.9% during the 2nd quarter. North Growth Management Ltd. now owns 593,000 shares of the healthcare company’s stock valued at $10,821,000 after acquiring an additional 63,000 shares in the last quarter. Finally, Means Investment CO. Inc. purchased a new stake in InMode during the 2nd quarter worth $285,000. 68.04% of the stock is owned by institutional investors and hedge funds.

InMode Price Performance

Shares of InMode stock opened at $19.02 on Friday. InMode Ltd. has a 1-year low of $14.87 and a 1-year high of $26.80. The business has a 50-day moving average of $17.40 and a 200-day moving average of $17.46. The company has a market capitalization of $1.60 billion, a PE ratio of 10.28 and a beta of 2.15.

Analyst Ratings Changes

Several research firms have commented on INMD. Barclays cut their price objective on InMode from $29.00 to $27.00 and set an “overweight” rating on the stock in a research report on Monday, October 14th. Needham & Company LLC reiterated a “hold” rating on shares of InMode in a report on Thursday, October 31st. Finally, BTIG Research started coverage on InMode in a report on Thursday, October 17th. They issued a “buy” rating and a $25.00 price target for the company. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $22.60.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.